IL202616D0 - Substituted imidazoheterocycles - Google Patents

Substituted imidazoheterocycles

Info

Publication number
IL202616D0
IL202616D0 IL202616A IL20261609A IL202616D0 IL 202616 D0 IL202616 D0 IL 202616D0 IL 202616 A IL202616 A IL 202616A IL 20261609 A IL20261609 A IL 20261609A IL 202616 D0 IL202616 D0 IL 202616D0
Authority
IL
Israel
Prior art keywords
imidazoheterocycles
substituted
substituted imidazoheterocycles
Prior art date
Application number
IL202616A
Original Assignee
Cara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US93675407P priority Critical
Priority to US99442207P priority
Priority to US839507P priority
Priority to PCT/US2008/067632 priority patent/WO2008157751A2/en
Application filed by Cara Therapeutics Inc filed Critical Cara Therapeutics Inc
Publication of IL202616D0 publication Critical patent/IL202616D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IL202616A 2007-06-21 2009-12-09 Substituted imidazoheterocycles IL202616D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US93675407P true 2007-06-21 2007-06-21
US99442207P true 2007-09-19 2007-09-19
US839507P true 2007-12-19 2007-12-19
PCT/US2008/067632 WO2008157751A2 (en) 2007-06-21 2008-06-20 Substituted imidazoheterocycles

Publications (1)

Publication Number Publication Date
IL202616D0 true IL202616D0 (en) 2010-06-30

Family

ID=40137137

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202616A IL202616D0 (en) 2007-06-21 2009-12-09 Substituted imidazoheterocycles

Country Status (14)

Country Link
US (2) US7517874B2 (en)
EP (1) EP2170350B1 (en)
JP (1) JP5485148B2 (en)
KR (1) KR101605210B1 (en)
CN (1) CN101686989B (en)
AU (1) AU2008265655B2 (en)
BR (1) BRPI0812504B1 (en)
CA (1) CA2691776C (en)
EA (1) EA201000046A1 (en)
ES (1) ES2439255T3 (en)
IL (1) IL202616D0 (en)
MY (1) MY146924A (en)
NZ (1) NZ582760A (en)
WO (1) WO2008157751A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
PT1494732E (en) 2002-03-20 2008-03-20 Mannkind Corp Inhalation apparatus
AT486064T (en) 2004-08-20 2010-11-15 Mannkind Corp Catalysis of diketopiperazine synthesis
CN104436170B (en) 2004-08-23 2018-02-23 曼金德公司 Diketopiperazine salt for drug delivery
AU2006290227B2 (en) 2005-09-14 2012-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
RU2403059C2 (en) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Method of improving pharmaceutical properties of particles, containing diketopiperazine and active agent
EA201000046A1 (en) * 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. Substituted imidasogeterocycles
US8859538B2 (en) * 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
WO2009032754A2 (en) * 2007-08-31 2009-03-12 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
CN101468988A (en) * 2007-12-26 2009-07-01 上海恒瑞医药有限公司 Piperazine derivative, preparation thereof and use thereof in medicine
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
US8499757B2 (en) 2008-06-13 2013-08-06 Mannkind Corporation Dry powder inhaler and system for drug delivery
EP2300083B1 (en) 2008-06-20 2013-05-22 MannKind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
TWI494123B (en) 2008-08-11 2015-08-01 Mannkind Corp Use of ultrarapid acting insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
TW201030007A (en) * 2009-02-06 2010-08-16 Gruenenthal Gmbh Substituted spiro-amides as b1r modulators
TW201035102A (en) * 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
DK2405963T3 (en) 2009-03-11 2013-12-16 Mannkind Corp Device, system and procedure for measuring resistance in an inhalator
CN101899048B (en) * 2009-05-27 2013-04-17 上海恒瑞医药有限公司 Salt of (R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1- carboxylic acid methyl ester
WO2010144789A2 (en) 2009-06-12 2010-12-16 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EA023586B1 (en) 2009-08-28 2016-06-30 Арена Фармасьютикалз, Инк. Cannabinoid receptor modulators, pharmaceutical composition comprising same, and uses thereof
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
DK2552920T3 (en) 2010-04-02 2017-06-12 Ogeda Sa Unknown unknown nk-3 receptor selective antagonist relations, pharmaceutical composition and methods for use in nk-3 receptor-medium disorders
RU2571331C1 (en) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Systems and methods for dry powder drug delivery
CN102464661B (en) * 2010-11-16 2015-04-01 天津药明康德新药开发有限公司 Preparation method of 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylic acid ethyl ester
HU1000676D0 (en) * 2010-12-17 2011-02-28 Pharmahungary 2000 Kft Inhibitors of matrix metalloproteinase, pharmaceutical compositions thereof and use of them for preventing and treating diseases where the activation of mmp is involved
MX346533B (en) 2011-02-25 2017-03-14 Arena Pharm Inc Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators).
EP3385252A1 (en) 2011-02-25 2018-10-10 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012116277A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
JP6133270B2 (en) 2011-04-01 2017-05-24 マンカインド コーポレイション Blister packaging for drug cartridge
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US9475814B2 (en) 2011-10-03 2016-10-25 Euroscreen S.A. Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
RU2650035C2 (en) 2012-07-12 2018-04-06 Маннкайнд Корпорейшн Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP2968316B1 (en) * 2013-03-13 2019-08-07 Forma Therapeutics, Inc. 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer
JP6523247B2 (en) 2013-03-15 2019-05-29 マンカインド コーポレイション Method of making microcrystalline diketopiperazine particles and method of making dry powder composition
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
SG11201604878XA (en) * 2013-12-20 2016-07-28 Esteve Labor Dr Fused imidazolyl derivatives, their preparation and use as medicaments
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
AU2018207776A1 (en) 2017-01-10 2019-07-18 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
AR113206A1 (en) 2017-01-10 2020-02-19 Bayer Cropscience Ag Heterocyclic derivatives as pesticides
EP3660018A1 (en) 2017-07-27 2020-06-03 Jiangsu Hengrui Medicine Co., Ltd. Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine
WO2019191667A1 (en) * 2018-03-29 2019-10-03 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2617478B1 (en) 1987-07-01 1990-01-05 Esteve Labor Dr Novel aryl-heteroaryl cetones derivatives, their preparation process and their application as medicaments
JPH07101959A (en) 1993-09-30 1995-04-18 Sankyo Co Ltd 1-methylcarbapenem derivative
JPH07101957A (en) 1993-10-06 1995-04-18 Asahi Glass Co Ltd Cyclic prostaglandin derivative and its production
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JPH08325234A (en) 1995-05-30 1996-12-10 Yamanouchi Pharmaceut Co Ltd Benzoic acid derivative or its salt
CA2432578C (en) 2001-01-02 2008-04-01 F. Hoffmann-La Roche Ag Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
US6960595B2 (en) 2001-03-23 2005-11-01 Bristol-Myers Squibb Pharma Company 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
BR0211729A (en) * 2001-08-09 2004-08-24 Actelion Pharmaceuticals Ltd Compounds, pharmaceutical compositions, process for manufacturing compounds, use of one or more compounds, and process for manufacturing pharmaceutical compositions
WO2003068776A1 (en) 2002-02-15 2003-08-21 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
DE60307483T2 (en) 2002-08-07 2007-07-05 Novartis Ag Organic compounds as a means for the treatment of alterosterone-conditioning states
SE0203070D0 (en) 2002-10-16 2002-10-16 Astrazeneca Ab Novel compounds
CA2507026A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivatives, their production and use
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) * 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
JP2009513504A (en) 2003-07-02 2009-04-02 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 5-substituted quinazolinone derivatives
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
JP4769082B2 (en) 2003-12-17 2011-09-07 武田薬品工業株式会社 Urea derivatives, their production and use
DE602004006166T2 (en) * 2003-12-19 2008-01-10 Bristol-Myers Squibb Co. Azabicyclic heterocycles as cannabinoid receptor modulators
BRPI0417771A (en) * 2003-12-19 2007-04-17 Squibb Bristol Myers Co azabicyclic heterocycles as cannabinoid receptor modulators
RU2266906C1 (en) 2004-04-29 2005-12-27 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Anellated carbamoyl azaheterocycles, methods for their preparing (variants), pharmaceutical composition, focused library
DE102004021716A1 (en) * 2004-04-30 2005-12-01 Grünenthal GmbH Substituted imidazo [1,2-a] pyridine compounds and drugs containing substituted imidazo [1,2-a] pyridine compounds
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
EP1642577A1 (en) 2004-09-07 2006-04-05 Laboratorios del Dr. Esteve S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of central neuropathic pain
AR051596A1 (en) * 2004-10-26 2007-01-24 Irm Llc Condensed nitrogenous heterocyclic compounds as inhibitors of the cannabinoid activity 1 receptor; pharmaceutical compositions containing them and their use in the preparation of medicaments for the treatment of eating disorders
AU2005302697B2 (en) * 2004-10-27 2012-09-13 Janssen Pharmaceutica, N.V. Tetrahydro pyridinyl pyrazole cannabinoid modulators
WO2006087147A2 (en) 2005-02-15 2006-08-24 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
US7629342B2 (en) * 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
RU2281947C1 (en) 2005-07-05 2006-08-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Anellated cabamoylazaheterocycles, focused library, pharmaceutical composition and method for its preparing
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
BRPI0710107A2 (en) * 2006-03-30 2011-08-02 Irm Llc compound, composition comprising the same as well as use thereof
RU2318818C1 (en) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Azaheterocycles, combinatory library, focused library, pharmaceutical composition and method for preparing (variants)
EP2019677B1 (en) 2006-05-16 2013-08-14 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007139992A2 (en) 2006-05-26 2007-12-06 Novartis Ag ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
WO2008017932A2 (en) 2006-08-09 2008-02-14 Pfizer Products Inc. Heterocycles useful as inhibitors of carbonic anhydrase
EA201000046A1 (en) * 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. Substituted imidasogeterocycles
CN101468988A (en) * 2007-12-26 2009-07-01 上海恒瑞医药有限公司 Piperazine derivative, preparation thereof and use thereof in medicine

Also Published As

Publication number Publication date
EP2170350B1 (en) 2013-09-11
NZ582760A (en) 2011-12-22
CA2691776A1 (en) 2008-12-24
CN101686989A (en) 2010-03-31
CN101686989B (en) 2016-10-19
KR20100050459A (en) 2010-05-13
AU2008265655A1 (en) 2008-12-24
ES2439255T3 (en) 2014-01-22
EA201000046A1 (en) 2011-02-28
EP2170350A4 (en) 2011-09-28
US20080318935A1 (en) 2008-12-25
KR101605210B1 (en) 2016-03-21
US20090149450A1 (en) 2009-06-11
WO2008157751A3 (en) 2009-03-12
WO2008157751A2 (en) 2008-12-24
MY146924A (en) 2012-10-15
JP5485148B2 (en) 2014-05-07
AU2008265655B2 (en) 2014-02-06
CA2691776C (en) 2016-05-10
US8431565B2 (en) 2013-04-30
BRPI0812504B1 (en) 2019-12-03
BRPI0812504A2 (en) 2015-06-16
EP2170350A2 (en) 2010-04-07
US7517874B2 (en) 2009-04-14
JP2010530891A (en) 2010-09-16

Similar Documents

Publication Publication Date Title
NL300959I2 (en) tildrakizumab
IL244498D0 (en) Micromirs
LU92936I2 (en) Keytruda
HK1143162A1 (en) Polymorphe rotigotin-form
GB0706793D0 (en) Compounds
EP2212908A4 (en) Fin-jfet
PL2190368T3 (en) Transconnector
DE602008004546D1 (en) Nanofläche
IL202616D0 (en) Substituted imidazoheterocycles
GB0718224D0 (en) E;ectricalsupply revies
DE602008001376D1 (en) Integriertes waking-/-while-awake-power-management-system
GB0704407D0 (en) Compounds
DE602008004757D1 (en) Oximesther-fotoinitiatoren
DE602008003124D1 (en) 1-butenethylencopolymere
ZA201001683B (en) Substituted piperidino-dihydrothienopyrimidines
GB2454992B (en) Playard
GB0706633D0 (en) Combination
GB0822049D0 (en) Teleskopierbare lenkspindelanordnung
DE602008004500D1 (en) Fifo-puffer
GB0709534D0 (en) Compounds
GB0702456D0 (en) New combination
IL201021D0 (en) Diphenyl-dihydro-imidazopyridinones
DE602008005470D1 (en) Imidazopyridinone
GB0707123D0 (en) Roulette-plus roulette-treble
GB0704394D0 (en) Compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed